After building pipelines from GlaxoSmithKline to Flagship, Paul Peter Tak takes the helm at an under-the-radar oncolytic virus player

Amber Tong

Paul Peter Tak has done it all: From a professorship in his native Netherlands to the head of immunoinflammation R&D at GlaxoSmithKline, from leading small …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

After building pipelines from GlaxoSmithKline to Flagship, Paul Peter Tak takes the helm at an under-the-radar oncolytic virus player

Amber Tong

Sign up to read this article for free.

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure

Af­ter build­ing pipelines from Glax­o­SmithK­line to Flag­ship, Paul Pe­ter Tak takes the helm at an un­der-the-radar on­colyt­ic virus play­er

Amber Tong

Sign up to read this article for free.

more like this

Deputy FDA chief mulls shak­ing up PDU­FA reau­tho­riza­tion struc­ture

Up­dat­ed: No­vo Nordisk CEO to step down amid stock de­cline, time­line for suc­ces­sor un­known

The in­side sto­ry of the six-month sprint to cre­ate the first cus­tom CRISPR ther­a­py for one in­fant’s rare dis­ease

Low­er at­ten­dance at cell and gene ther­a­py con­fer­ence mir­rors chal­lenged in­dus­try

FDA pos­es ef­fi­ca­cy, safe­ty ques­tions over four can­cer drugs ahead of two-day ad­comm

'Go ahead and do it': Top RFK Jr. deputy dares drug­mak­ers that might pull man­u­fac­tur­ing over new price pres­sure

After building pipelines from GlaxoSmithKline to Flagship, Paul Peter Tak takes the helm at an under-the-radar oncolytic virus player

Deputy FDA chief mulls shaking up PDUFA reauthorization structure

Updated: Novo Nordisk CEO to step down amid stock decline, timeline for successor unknown

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Lower attendance at cell and gene therapy conference mirrors challenged industry

FDA poses efficacy, safety questions over four cancer drugs ahead of two-day adcomm

'Go ahead and do it': Top RFK Jr. deputy dares drugmakers that might pull manufacturing over new price pressure